LYRDROI

Serial Number 97526360
Registration 7031118
700

Registration Progress

Application Filed
Jul 29, 2022
Under Examination
Approved for Publication
Jan 31, 2023
Published for Opposition
Jan 31, 2023
Registered
Apr 18, 2023

Trademark Image

LYRDROI

Basic Information

Serial Number
97526360
Registration Number
7031118
Filing Date
July 29, 2022
Registration Date
April 18, 2023
Published for Opposition
January 31, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 18, 2023
Registration
Registered
Classes
005

Rights Holder

Glaxo Group Limited

99
Address
980 Great West Road
Brentford, Middlesex TW89GS

Ownership History

Glaxo Group Limited

Original Applicant
99
Brentford, Middlesex

Glaxo Group Limited

Owner at Publication
99
Brentford, Middlesex

Glaxo Group Limited

Original Registrant
99
Brentford, Middlesex

Legal Representation

Attorney
Elizabeth Rucki

USPTO Deadlines

Next Deadline
1185 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20230418)
Due Date
April 18, 2029
Grace Period Ends
October 18, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

9 events
Date Code Type Description Documents
Apr 18, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Apr 18, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jan 31, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 31, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 11, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 28, 2022 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 27, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 20, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 2, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

Classification

International Classes
005